

## Defensin HNP-1 human TFA

<b>Cat. No.:</b>	HY-P2310A
<b>Molecular Formula:</b>	C <sub>152</sub> H <sub>223</sub> F <sub>3</sub> N <sub>44</sub> O <sub>40</sub> S <sub>6</sub>
<b>Molecular Weight:</b>	3556.05
<b>Sequence:</b>	Ala-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys (Disulfide bridge:Cys2-Cys30,Cys4-Cys19,Cys9-Cys29)
<b>Sequence Shortening:</b>	ACYCRIPACIAGERRYGTCTIYQGRLWAFCC (Disulfide bridge:Cys2-Cys30,Cys4-Cys19,Cys9-Cys29)
<b>Target:</b>	Bacterial; Parasite
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Sealed storage, away from moisture Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### BIOLOGICAL ACTIVITY

<b>Description</b>	Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities [1][2].
<b>IC<sub>50</sub> &amp; Target</b>	Leishmania

### REFERENCES

- [1]. Dabirian S, et, al. Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate. PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2491.
- [2]. Higazi M, et, al. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis. PLoS One. 2020 Apr 17;15(4):e0231582.
- [3]. Higazi M, et al. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis. PLoS One. 2020 Apr 17;15(4):e0231582.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA